Keywords: acute periprosthetic joint infection (PJI); antibiotic combination; antibiotic duration; antibiotic therapy; antibiotic treatment; biofilm; chronic obstructive pulmonary disease (COPD)), and C-reactive protein (CRP) >115 mg/L (C), rheumatoid arthritis (R), indication prosthesis (I), male (M), exchange of mobile components (E), age > 80 years (80) (CRIME80) scores; chronic renal failure (K), liver cirrhosis (L), index surgery (I), cemented prosthesis (C), and C-reactive protein (CRP) >115 mg/L (KLIC) score; contraindications; debridement antibiotics and retention of the prosthesis; debridement, antibiotics, implant retention (DAIR); emergency management; exchange of modular components; failed debridement, antibiotics, implant retention (DAIR) management; fluoroquinolone; gram-negative acute periprosthetic joint infection (PJI); indications; infection recurrence; intra-articular antibiotic infusion; irrigation; irrigation and debridement; irrigation solution; length of antibiotics; megaprosthesis; methicillin-resistant Staphylococcus aureus (MRSA); pathogen identification; patient optimization; periprosthetic joint infection (PJI) recurrence; povidone-iodine; rifampicin; risk stratification; surgical factors; surgical intervention; surgical outcome; surgical outcomes; surgical site infection (SSI) recurrence; surgical timing; treatment failure; treatment success; two-stage exchange arthroplasty; unicompartmental knee arthroplasty debridement, antibiotics, implant retention (DAIR).